N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.

BACKGROUND Atrial natriuretic factor (ANF) is a peptide hormone secreted from cardiac atria in response to increased atrial pressure. Because of a longer half-life and greater stability, the N-terminal of ANF prohormone (N-terminal proANF) may be a better integrator of atrial peptide secretion than ANF itself. After myocardial infarction, elevation of ANF and other neurohormones has been associated with a poor prognosis. However, when left ventricular ejection fraction (LVEF) and other important clinical variables are included in multivariate analysis, the independent predictive value of these neurohormones has been reduced markedly. METHODS AND RESULTS To test the prognostic value of N-terminal proANF after myocardial infarction, its plasma concentration was measured a mean of 12 days after infarction in 246 patients in the Survival and Ventricular Enlargement (SAVE) Study. N-terminal proANF was a much stronger predictor of survival than ANF itself. Furthermore, in multivariate analysis of cardiovascular mortality and development of heart failure, N-terminal proANF in contrast to ANF and other neurohormones was still a powerful and independent predictor when the model included age, gender, prior myocardial infarction, hypertension, diabetes, use of thrombolysis, Killip class, infarct location, and LVEF. CONCLUSIONS The measurement of N-terminal proANF supplements presently used clinical and objective assessments and provides an important independent predictor of prognosis with respect to cardiovascular mortality and development of heart failure.

[1]  P. Mathisen,et al.  Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. , 1993, Scandinavian journal of clinical and laboratory investigation.

[2]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[3]  J. Dimsdale,et al.  Plasma Atrial Natriuretic Peptide Is Unstable Under Most Storage Conditions , 1992, Circulation.

[4]  T. Pindborg,et al.  Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction , 1992, British heart journal.

[5]  K. Minaker,et al.  Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. , 1992, JAMA.

[6]  T. Maack Receptors of atrial natriuretic factor. , 1992, Annual review of physiology.

[7]  M. Pfeffer,et al.  Rationale, design and baseline characteristics of the survival and ventricular enlargement trial , 1991 .

[8]  G. Lamas,et al.  Activation of neurohumoral systems following acute myocardial infarction. , 1991, The American journal of cardiology.

[9]  M. A. Plant Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[10]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[11]  D. vesely,et al.  Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distension. , 1991, The American journal of physiology.

[12]  D. vesely,et al.  The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. , 1989, Circulation.

[13]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[14]  T. Hintze,et al.  Atrial wall function and plasma atriopeptin during volume expansion in conscious dogs. , 1989, The American journal of physiology.

[15]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[16]  N. Seidah,et al.  NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: Identification, radioimmunoassay and half-life , 1988, Peptides.

[17]  R. Zimmerman,et al.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. , 1988, Circulation research.

[18]  H. Itoh,et al.  Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP. , 1988, The Journal of clinical endocrinology and metabolism.

[19]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[20]  A. Kenny,et al.  The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. , 1987, The Biochemical journal.

[21]  S. Ball,et al.  Plasma alpha natriuretic peptide in cardiac impairment. , 1986, British medical journal.

[22]  R. Cuneo,et al.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. , 1986, Life sciences.

[23]  J. Rouleau,et al.  Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. , 1986, Circulation.

[24]  J. Wade,et al.  Heterologous radioimmunoassay of atrial natriuretic polypeptide in dog and rabbit plasma. , 1986, Journal of immunoassay.

[25]  K. Kangawa,et al.  Molecular forms of atrial natriuretic polypeptides in mammalian tissues and plasma. , 1985, Biochemical and biophysical research communications.

[26]  J. Dietz Release of natriuretic factor from rat heart-lung preparation by atrial distension. , 1984, The American journal of physiology.

[27]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[28]  T. Flynn,et al.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. , 1983, Biochemical and biophysical research communications.

[29]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[30]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.